Henri Termeer

Henri Termeer Overview

Investor Type Angel
Status Active
Professionals 1
Investments 9
Portfolio 4
Exits 2

Henri Termeer General Information


Dr. Henri Termeer Co-Founded & served as Supervisory Board Member at ProQR Therapeutics. From October 1983 to June 2011, Henri served as chairman, president and chief executive officer of Genzyme Corporation. For ten years prior to joining Genzyme, Henri worked for Baxter International Laboratories, Inc., a manufacturer of human health care products. Henri resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi. Widely acknowledged for his contributions to the biotechnology industry and health care field, Henri was active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. He was a member of the board of each of Massachusetts General Hospital and Partners HealthCare and a member of the board of fellows of Harvard Medical School. Henri was also a member of the board of the Massachusetts Institute of Technology and serves on its Executive Committee and a board member of the Biotechnology Industry Organization (BIO). He was chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. Henri was a board member of ProQR Therapeutics N.V., Abiomed Inc., Aveo Pharmaceuticals, Verastem, Inc., Moderna Therapeutics and Medical Simulation, and was a board member of Allergan, Inc. from 2014 through its acquisition by Actavis in March 2015. In 2008, he was appointed to Massachusetts Governor Deval Patrick's Council of Economic Advisors. Henri was chairman of the Federal Reserve Bank of Boston's board of directors from 2010-2011. Henri studied economics at the Economische Hogeschool (Erasmus University, the Netherlands) and earned an MBA from the Darden School at the University of Virginia.

Contact Information

Investor Status
Actively Seeking New Investments
Primary Investor Type
Angel (individual)
Primary Office
  • United States

Henri Termeer Investments (9)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Arrakis Therapeutics 10-Apr-2019 Early Stage VC 0000 Drug Discovery Generating Revenue 00000 0000000 00.0
0000 00000000000 13-Dec-2018 00000 00000 000.00 Biotechnology Clinical Trials - Phase 1 00000 0000000 00.0
0000000 0000000000 02-Mar-2017 00000 00000 000.00 Drug Discovery Generating Revenue 00000 0000000 00.0
000000 22-Aug-2016 00000 00000 000 Biotechnology Generating Revenue 00000 0000000 00.0
00000 000000 07-Dec-2015 00000 00000 00.000 Other Healthcare Technology Systems Generating Revenue 00000 0000000 00.0
00000 000000000 22-Sep-2015 00000 00000 0000 Biotechnology Generating Revenue 00000 0000000 00.0
00 000000000000000 28-Aug-2015 00000 00000 000.00 Biotechnology Generating Revenue 00000 0000000 00.0
Aura Biosciences 05-Mar-2015 Later Stage VC 0000 Biotechnology Clinical Trials - Phase 1 00000 0000000 00.0
NanoString Technologies 07-Nov-2011 Later Stage VC 000.00 Biotechnology Generating Revenue/Not Profitable 00000 0000000 00.0
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Henri Termeer Exits (2)

To view Henri Termeer‘s complete exit history, request access >>
Company Name Exit Date Exit Type Exit Size
Twine Health 01-Feb-2018 Merger/Acquisition 000.00
00 000000000000000 000000000 00000000

Henri Termeer Team (1)

Name Title Deals Funds Boards Office
Henri Termeer Ph.D Angel Investor 0